Charles D. Scher

Quiescent BALB/c 3T3 cells exposed briefly to a platelet-derived growth factor (PDGF) become "competent" to replicate their DNA but do not "progress" into S phase unless incubated with growth factors contained in platelet-poor plasma. Plasma from hypophysectomized rats is deficient in progression activity; it does not stimulate PDGF-treated competent cells to synthesize DNA, demonstrating that somatomedin C is required for progression. Various growth factors were tested for progression activity and competence activity by using BALB/c 3T3 tissue culture assays. Multiplication stimulating activity and other members of the somatomedin family of growth factors are (like somatomedin C) potent mediators of progression. Other mitogenic agents, such as fibroblast growth factor, are (like PDGF) potent inducers of competence. Growth factors with potent progression activity have little or no competence activity and vice versa. In contrast, simian virus 40 provides both competence and progression activity. Coordinate control of BALB/c 3T3 cell growth in vitro by competence factors and somatomedins may be a specific example of a common pattern of growth regulation in animal tissues.

Serum contains a growth factor derived from platelets and also growth factors derived from platelet-poor plasma. Extracts of heated (100 degrees ) human platelets function synergistically with platelet-poor plasma to induce DNA synthesis in quiescent, density-inhibited BALB/c 3T3 cells. Platelet-poor plasma alone did not induce DNA synthesis. Cells exposed to platelet extracts became competent to enter the cell cycle, but the rate of entry into the S phase depended upon the concentration of platelet-poor plasma. The time required for the induction of this competent state was a function of the concentration of the platelet extract. A 2-hr exposure to 100 mug of the platelet extract at 37 degrees caused the entire cell population to become competent to enter the S phase. At 4 degrees or 25 degrees the cells did not become competent to synthesize DNA. The platelet extract-induced competent state was stable for at least 13 hr after removal of the platelet extract; however, in the absence of platelet-poor plasma, these competent cells did not progress through the cell cycle. The addition of an optimal concentration of platelet-poor plasma (5%) to these competent cells initiated cell cycle traverse with a rapid, first-order entry of cells into the S phase beginning 12 hr after addition of the plasma. The addition of a suboptimal concentration of the plasma (0.25%) did not increase the rate of cell entry into the S phase. Thus, the induction of DNA synthesis in quiescent BALB/c 3T3 cells can be resolved into at least two phases, controlled by different serum components: (i) competence, induced by the platelet-derived growth factor; and (ii) progression of competent cells into the cell cycle, mediated by factors in platelet-poor plasma.

Human platelets contain a polypeptide growth factor that stimulates the proliferation of connective tissue cells. Purification of this platelet-derived growth factor (PDGF) was accomplished by heat (100 degrees C) treatment of washed platelets and subsequent ion-exchange chromatography, gel filtration in 1 M acetic acid, isoelectric focusing, and preparative sodium dodecyl sulfate/polyacrylamide gel electrophoresis. PDGF has an isoelectric point of 9.8 and a molecular weight ranging from 13,000 to 16,000 as judged by gel filtration in 1 M acetic acid or analytical sodium dodecyl sulfate gel electrophoresis under reducing conditions. The specific activity of the purified PDGF is 20 million times greater than that found in unfractionated human serum. Purified PDGF stimulates replicative DNA synthesis and cell proliferation in quiescent density-arrested cultures of BALB/c 3T3 cells at concentrations of 1 ng/ml (0.1 nM).

An ordered sequence of events must be completed before cells become committed to synthesize DNA. A platelet-derived growth factor (PDGF), present in heated (100 degrees ) extracts of human platelets, induces density-inhibited BALB/c-3T3 cells to become competent to proliferate. Platelet-poor plasma induces these competent cells to leave the competence point, progress through G(0)/G(1), and enter the S phase. Treatment of G(0)-arrested, incompetent cells with plasma, before the addition of PDGF, did not shorten the latent period for DNA synthesis or increase the rate of entry into the S phase. Growth arrest points in the plasma-dependent progression sequence were detected in G(0)/G(1). PDGF-treated competent cells were exposed to an optimal concentration of plasma (5%) for various lengths of time and were then transferred to medium lacking plasma; the subsequent readdition of plasma stimulated the cells to enter the S phase. The lag period until DNA synthesis, in such experiments, was dictated by the length of the initial exposure to plasma. PDGF-treated competent cells that were incubated with plasma for 5 hr during the initial exposure did not leave the competence point; they began DNA synthesis 12 hr after the readdition of plasma. However, a population of cells treated with plasma for 10 hr became arrested at a point 6 hr before DNA synthesis, whereas a population treated with plasma for 12-15 hr became arrested at a point immediately before DNA synthesis. Cells remained arrested at this latter point for as long as 24 hr, and these arrested cells were not committed to DNA synthesis. The addition of plasma induced immediate entry into the S phase with an apparent first-order rate of entry being determined by the plasma concentration. This plasma-dependent commitment (transition) to DNA synthesis was blocked by cycloheximide but not by hydroxyurea. Removal of the hydroxyurea allowed cells to enter the S phase synchronously in the absence of plasma.